GENE ONLINE|News &
Opinion
Blog

2022-10-25| Trials & Approvals

Janssen Scores Another Multiple Myeloma FDA Approval with Tecvayli

by Reed Slater
Share To

After the European Commission approved Janssen’s multiple myeloma treatment, Tecvayli, in August, the company received notice that the FDA approved the drug in the U.S. through the accelerated approval pathway as a late-line therapy on October 25. Tecvayli marks Janssen’s fourth FDA-approved treatment for multiple myeloma and the first bispecific T-cell treatment for the disease.

Tecvayli as the First Bispecific T-Cell Treatment for Multiple Myeloma

An incurable blood cancer affecting plasma cells in bone marrow, multiple myeloma is a devastating disease impacting tens of thousands of Americans yearly. Early treatment lines for multiple myeloma often include a proteasome inhibitor, an immunomodulator agent, and an anti-CD38 monoclonal antibody.

The FDA approved Tecvayli as a late-line therapy for multiple myeloma patients who underwent at least four lines of previous treatment. The drug could be a valuable asset for patients who have experienced multiple relapses after prior therapies. 

Tecvayli is a bispecific T-cell engager antibody administered subcutaneously. Janssen designed the therapy to activate the immune system by binding to the CD3 receptor on T-cells and to the B-cell maturation antigen (BCMA) on multiple myeloma cells’ surfaces and some healthy B-lineage cells.

Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head of Oncology at Janssen, said, “Today’s achievement, which marks an important addition to our diverse and growing oncology portfolio, strengthens our resolve to discover and develop much-needed cancer treatments for patients and physicians.”

The FDA approved Tecvayli based on data from the MajesTEC-1 study. The drug only underwent two clinical trial phases and may require confirmatory trials to gain regular approval or approval for other indications. 

Related Article: Johnson & Johnson’s Multiple Myeloma Treatment Wins Accelerated Approval

Achieving 61.8% ORR in Phase 2 Trials

The Phase 2 leg of the MajesTEC-1 study recruited 192 participants who received at least three lines of prior therapy for multiple myeloma. Janssen said that 78% received four or more lines of previous therapy, and all received a proteasome inhibitor, an immunomodulator agent, and an anti-CD38 monoclonal antibody. 

During the Phase 2 clinical trial, patients started with small Tecvayli doses of 0.3 mg/kg to 0.6 mg/kg before stepping up to the recommended 1.5 mg/kg. Participants received weekly treatments of the recommended dose or until disease progression or unacceptable toxicity. 

The study’s primary endpoints included overall response rate (ORR) or unacceptable toxicity, with secondary endpoints including duration of response, very good partial response, complete response, time to response, and many more. Tecvayli demonstrated an ORR of 61.8%, meeting the primary endpoint. For a secondary endpoint, Tecvayli demonstrated a 28.2% complete response rate, ticking another box for the drug.

Already a leader in the multiple myeloma space, Tecvayli’s accelerated approval plunges Janssen deeper into the area. The European approval marked a sign of good things to come for the drug, and now with the FDA’s stamp, Tecvayli is ready to hit the U.S. market and serve multiple myeloma patients with at least four lines of previous therapy. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
SystImmune Partners with Bristol-Myers Squibb to Develop and Commercialize Bispecific ADC Globally
2023-12-13
F-star Announces Collaboration with Takeda to Develop Next Generation Immunotherapeutics
2023-07-09
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top